JP2007511485A - Ｐｐａｒアゴニストとしての置換ピラゾール - Google Patents
Ｐｐａｒアゴニストとしての置換ピラゾール Download PDFInfo
- Publication number
- JP2007511485A JP2007511485A JP2006538823A JP2006538823A JP2007511485A JP 2007511485 A JP2007511485 A JP 2007511485A JP 2006538823 A JP2006538823 A JP 2006538823A JP 2006538823 A JP2006538823 A JP 2006538823A JP 2007511485 A JP2007511485 A JP 2007511485A
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- phenyl
- pyrazol
- amino
- carbonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC=CC(*C(*)=CC(C)=N)=CC Chemical compound CC=CC(*C(*)=CC(C)=N)=CC 0.000 description 6
- IAKHPEWQALEFAJ-UHFFFAOYSA-N CC(C)(C(O)=O)OC1C(C)=CC=CC1 Chemical compound CC(C)(C(O)=O)OC1C(C)=CC=CC1 IAKHPEWQALEFAJ-UHFFFAOYSA-N 0.000 description 1
- BRKZKXVRXXPOEA-UHFFFAOYSA-N CC(C)(C(O)=O)Oc1c(C)cc(CNC(CCl)=O)cc1 Chemical compound CC(C)(C(O)=O)Oc1c(C)cc(CNC(CCl)=O)cc1 BRKZKXVRXXPOEA-UHFFFAOYSA-N 0.000 description 1
- IOSMRGMGAZMMBG-UHFFFAOYSA-N CC(C)(C(O)=O)Oc1c(C)cc(CNC(c2n[n](C)c(-c3cccc(N4CCCC4)c3)c2)=O)cc1 Chemical compound CC(C)(C(O)=O)Oc1c(C)cc(CNC(c2n[n](C)c(-c3cccc(N4CCCC4)c3)c2)=O)cc1 IOSMRGMGAZMMBG-UHFFFAOYSA-N 0.000 description 1
- WYMATXQLTLNEIC-UHFFFAOYSA-N CC(C)(C(O)=O)Oc1ccc(CNC(c2cc(-c(cc3)ccc3O)n[n]2C)=O)cc1C Chemical compound CC(C)(C(O)=O)Oc1ccc(CNC(c2cc(-c(cc3)ccc3O)n[n]2C)=O)cc1C WYMATXQLTLNEIC-UHFFFAOYSA-N 0.000 description 1
- QWVAVDLPTMWMGV-UHFFFAOYSA-N CC(C)(C)c(cc1)ccc1-c1n[n](C)c(C(NCc(cc2)cc(C)c2OC(C)(C)C(O)=O)=O)c1 Chemical compound CC(C)(C)c(cc1)ccc1-c1n[n](C)c(C(NCc(cc2)cc(C)c2OC(C)(C)C(O)=O)=O)c1 QWVAVDLPTMWMGV-UHFFFAOYSA-N 0.000 description 1
- RWSQTZOKSVLYSJ-UHFFFAOYSA-N CC(C)(C)c(cc1)ccc1-c1n[n](C)c(C(NCc(cc2)cc(OC)c2OC(C)(C)C(O)=O)=O)c1 Chemical compound CC(C)(C)c(cc1)ccc1-c1n[n](C)c(C(NCc(cc2)cc(OC)c2OC(C)(C)C(O)=O)=O)c1 RWSQTZOKSVLYSJ-UHFFFAOYSA-N 0.000 description 1
- MNZSYDYUUQTJOB-UHFFFAOYSA-N CC(C)(C)c(cc1)ccc1-c1n[n](C)c(C(NCc(cc2)ccc2OC(C)(C)C(O)=O)=O)c1 Chemical compound CC(C)(C)c(cc1)ccc1-c1n[n](C)c(C(NCc(cc2)ccc2OC(C)(C)C(O)=O)=O)c1 MNZSYDYUUQTJOB-UHFFFAOYSA-N 0.000 description 1
- OPCCRUAQNXTYGB-UHFFFAOYSA-N CC(C)(C)c(cc1)ccc1-c1n[n](C)c(C(NCc(cc2C)cc(C)c2OC(C)(C)C(O)=O)=O)c1 Chemical compound CC(C)(C)c(cc1)ccc1-c1n[n](C)c(C(NCc(cc2C)cc(C)c2OC(C)(C)C(O)=O)=O)c1 OPCCRUAQNXTYGB-UHFFFAOYSA-N 0.000 description 1
- OFAAKYBHMFWXMQ-UHFFFAOYSA-N CC(C)(C)c(cc1)ccc1-c1n[n](Cc2ccccc2)c(C(O)=O)c1 Chemical compound CC(C)(C)c(cc1)ccc1-c1n[n](Cc2ccccc2)c(C(O)=O)c1 OFAAKYBHMFWXMQ-UHFFFAOYSA-N 0.000 description 1
- UYFJYGWNYQCHOB-UHFFFAOYSA-N CC(C)(C)c(cc1)ccc1C(C)=O Chemical compound CC(C)(C)c(cc1)ccc1C(C)=O UYFJYGWNYQCHOB-UHFFFAOYSA-N 0.000 description 1
- LWFSUQJKUZJKID-UVTDQMKNSA-O CCOC(/C(/[OH2+])=C/C(c1ccc(C(C)(C)C)cc1)=O)=O Chemical compound CCOC(/C(/[OH2+])=C/C(c1ccc(C(C)(C)C)cc1)=O)=O LWFSUQJKUZJKID-UVTDQMKNSA-O 0.000 description 1
- CUKUBKYMMLSBRO-UHFFFAOYSA-N CCOC(C(C)(C)Oc(ccc(CNC(c1cc(-c2ccc(C(C)(C)C)cc2)n[n]1C)=O)c1)c1OC)=O Chemical compound CCOC(C(C)(C)Oc(ccc(CNC(c1cc(-c2ccc(C(C)(C)C)cc2)n[n]1C)=O)c1)c1OC)=O CUKUBKYMMLSBRO-UHFFFAOYSA-N 0.000 description 1
- MFFDVDLHXXYDEH-UHFFFAOYSA-N CCOC(C(C)(C)Oc1c(C)cc(CN=C)cc1)=O Chemical compound CCOC(C(C)(C)Oc1c(C)cc(CN=C)cc1)=O MFFDVDLHXXYDEH-UHFFFAOYSA-N 0.000 description 1
- QHTHXXGTWXOBNA-UHFFFAOYSA-N CCOC(C(C)(C)Oc1c(C)cc(CNC(c2n[n](C)c(-c(cc3)ccc3Br)c2)=O)cc1)=O Chemical compound CCOC(C(C)(C)Oc1c(C)cc(CNC(c2n[n](C)c(-c(cc3)ccc3Br)c2)=O)cc1)=O QHTHXXGTWXOBNA-UHFFFAOYSA-N 0.000 description 1
- MUWFCGZCHRMZJA-UHFFFAOYSA-N CCOC(C(C)(C)Oc1c(C)cc(CNC(c2n[n](C)c(-c3ccc(C(C)C)cc3)c2)=O)cc1)=O Chemical compound CCOC(C(C)(C)Oc1c(C)cc(CNC(c2n[n](C)c(-c3ccc(C(C)C)cc3)c2)=O)cc1)=O MUWFCGZCHRMZJA-UHFFFAOYSA-N 0.000 description 1
- KLTSCYGDPCPUCA-UHFFFAOYSA-N CCOC(C(C)(C)Oc1c(C)cc(CNC(c2n[n](C)c(-c3ccc(CC(C)C)cc3)c2)=O)cc1)=O Chemical compound CCOC(C(C)(C)Oc1c(C)cc(CNC(c2n[n](C)c(-c3ccc(CC(C)C)cc3)c2)=O)cc1)=O KLTSCYGDPCPUCA-UHFFFAOYSA-N 0.000 description 1
- SQVRZNHYILQWQX-OQLLNIDSSA-N CCOC(C(C)(C)Oc1ccc(/C=N/O)cc1C)=O Chemical compound CCOC(C(C)(C)Oc1ccc(/C=N/O)cc1C)=O SQVRZNHYILQWQX-OQLLNIDSSA-N 0.000 description 1
- QNVGLRKTCYGKSU-UHFFFAOYSA-N CCOC(C(C)(C)Oc1ccc(CNC(c2cc(-c3ccc(C(C)(C)C)cc3)n[n]2CC=C)=O)cc1C)=O Chemical compound CCOC(C(C)(C)Oc1ccc(CNC(c2cc(-c3ccc(C(C)(C)C)cc3)n[n]2CC=C)=O)cc1C)=O QNVGLRKTCYGKSU-UHFFFAOYSA-N 0.000 description 1
- DGDXNYAOVUEQTF-UHFFFAOYSA-N CCOC(c1cc(Cc2ccc(C(C)(C)C)cc2)n[n]1C)=O Chemical compound CCOC(c1cc(Cc2ccc(C(C)(C)C)cc2)n[n]1C)=O DGDXNYAOVUEQTF-UHFFFAOYSA-N 0.000 description 1
- XTCFTUFJWUUZKD-UHFFFAOYSA-N CC[n](c(-c1ccc(C(C)(C)C)cc1)c1)nc1C(NCc1ccc2OC(C)(C(OCC)=O)[O](C)c2c1)=O Chemical compound CC[n](c(-c1ccc(C(C)(C)C)cc1)c1)nc1C(NCc1ccc2OC(C)(C(OCC)=O)[O](C)c2c1)=O XTCFTUFJWUUZKD-UHFFFAOYSA-N 0.000 description 1
- OKQQGIUNGGGMDZ-UHFFFAOYSA-N CC[n](c(C(NCc(cc1OC)ccc1OC(C)(C)C(N)=O)=O)c1)nc1-c1ccc(C(C)(C)C)cc1 Chemical compound CC[n](c(C(NCc(cc1OC)ccc1OC(C)(C)C(N)=O)=O)c1)nc1-c1ccc(C(C)(C)C)cc1 OKQQGIUNGGGMDZ-UHFFFAOYSA-N 0.000 description 1
- BAKYASSDAXQKKY-UHFFFAOYSA-N Cc(cc(C=O)cc1)c1O Chemical compound Cc(cc(C=O)cc1)c1O BAKYASSDAXQKKY-UHFFFAOYSA-N 0.000 description 1
- QWVGKYWNOKOFNN-UHFFFAOYSA-N Cc(cccc1)c1O Chemical compound Cc(cccc1)c1O QWVGKYWNOKOFNN-UHFFFAOYSA-N 0.000 description 1
- TXNSZCSYBXHETP-UHFFFAOYSA-N OCNC(CCl)=O Chemical compound OCNC(CCl)=O TXNSZCSYBXHETP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0326747A GB0326747D0 (en) | 2003-11-17 | 2003-11-17 | Chemical compounds |
| GB0329462A GB0329462D0 (en) | 2003-12-19 | 2003-12-19 | Chemical compounds |
| PCT/EP2004/012965 WO2005049578A1 (en) | 2003-11-17 | 2004-11-15 | Substituted pyrazoles as ppar agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007511485A true JP2007511485A (ja) | 2007-05-10 |
| JP2007511485A5 JP2007511485A5 (https=) | 2007-08-09 |
Family
ID=34621661
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006538823A Pending JP2007511485A (ja) | 2003-11-17 | 2004-11-15 | Ｐｐａｒアゴニストとしての置換ピラゾール |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20080021030A1 (https=) |
| EP (1) | EP1685113B1 (https=) |
| JP (1) | JP2007511485A (https=) |
| AR (1) | AR046625A1 (https=) |
| AT (1) | ATE402926T1 (https=) |
| DE (1) | DE602004015498D1 (https=) |
| ES (1) | ES2311179T3 (https=) |
| TW (1) | TW200526588A (https=) |
| WO (1) | WO2005049578A1 (https=) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013513635A (ja) * | 2009-12-15 | 2013-04-22 | バイエル・クロップサイエンス・アーゲー | １−アルキル−／１−アリール−５−ピラゾールカルボン酸誘導体を調製する方法 |
| JP2013518823A (ja) * | 2010-02-08 | 2013-05-23 | バイオウタ サイエンティフィック マネジメント プロプライエタリー リミテッド | 呼吸器合胞体ウイルス感染症を治療するための化合物 |
| JP2016155812A (ja) * | 2010-03-30 | 2016-09-01 | ヴァーセオン コーポレイション | トロンビンの阻害剤としての多置換芳香族化合物 |
| US9687479B2 (en) | 2013-03-15 | 2017-06-27 | Verseon Corporation | Multisubstituted aromatic compounds as serine protease inhibitors |
| JP2017535568A (ja) * | 2014-11-27 | 2017-11-30 | カルビスタ・ファーマシューティカルズ・リミテッド | 血漿カリクレイン阻害剤としてのｎ−（（ヘタ）アリールメチル）−ヘテロアリール−カルボキサミド化合物 |
| US9951025B2 (en) | 2013-03-15 | 2018-04-24 | Verseon Corporation | Halogenopyrazoles as inhibitors of thrombin |
| US10189810B2 (en) | 2014-09-17 | 2019-01-29 | Verseon Corporation | Pyrazolyl-substituted pyridone compounds as serine protease inhibitors |
| US10532995B2 (en) | 2015-02-27 | 2020-01-14 | Verseon Corporation | Substituted pyrazole compounds as serine protease inhibitors |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080064682A1 (en) * | 2004-07-01 | 2008-03-13 | Daiichi Pharmaceutical Co., Ltd. | Pyrazole Derivatives |
| RU2007135745A (ru) * | 2005-02-28 | 2009-04-10 | Ниппон Кемифар Ко., Лтд. (JP) | АКТИВАТОР δ- РЕЦЕПТОРА, АКТИВИРУЕМОГО ПРОЛИФЕРАТОРОМ ПЕРОКСИСОМЫ |
| US8703805B2 (en) * | 2005-06-27 | 2014-04-22 | Exelixis Patent Company Llc | Modulators of LXR |
| CN101466687B (zh) | 2006-04-18 | 2012-04-11 | 日本化学医药株式会社 | 过氧化物酶体增殖剂激活受体δ的激活剂 |
| KR20090094125A (ko) | 2006-12-08 | 2009-09-03 | 엑셀리시스, 인코포레이티드 | Ｌｘｒ 및 ｆｘｒ 조절자 |
| JP2010523623A (ja) * | 2007-04-11 | 2010-07-15 | グラクソ グループ リミテッド | Ｐ２ｘ７調節因子としてのピラゾール誘導体 |
| MX2010011252A (es) | 2008-04-15 | 2010-11-30 | Nippon Chemiphar Co | Activador para el receptor activado por el proliferador de peroxisoma. |
| WO2010058858A1 (ja) * | 2008-11-21 | 2010-05-27 | ラクオリア創薬株式会社 | ５－ｈｔ２ｂ受容体拮抗活性を有する新規ピラゾール－３－カルボキサミド誘導体 |
| UY32826A (es) | 2009-08-04 | 2011-02-28 | Takeda Pharmaceutical | Compuestos heterocíclicos |
| CN101870676B (zh) * | 2010-06-24 | 2011-09-07 | 山东大学 | 1-(2-肟基-2-苯基乙基)-3-苯基-1h-吡唑-5-甲酸乙酯衍生物及其制备与应用 |
| TWI636047B (zh) | 2013-08-14 | 2018-09-21 | 英商卡爾維斯塔製藥有限公司 | 雜環衍生物 |
| GB201421085D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
| IL263235B (en) | 2016-05-31 | 2022-07-01 | Kalvista Pharmaceuticals Ltd | History of pyrazoles as plasma kallikrein inhibitors |
| GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| GB201609603D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
| CN110087667A (zh) | 2016-08-16 | 2019-08-02 | 隐形生物治疗公司 | Elamipretide的基于N-羧基酸酐的规模合成 |
| WO2018224455A1 (en) | 2017-06-07 | 2018-12-13 | Basf Se | Substituted cyclopropyl derivatives |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| HUE057912T2 (hu) | 2017-11-29 | 2022-06-28 | Kalvista Pharmaceuticals Ltd | Plazma kallikrein inhibitort tartalmazó dózisformák |
| TWI805699B (zh) | 2018-03-01 | 2023-06-21 | 日商日本煙草產業股份有限公司 | 甲基內醯胺環化合物及其用途 |
| MX2020010433A (es) | 2018-04-04 | 2020-10-28 | Japan Tobacco Inc | Compuestos de pirazol sustituidos con heteroarilo y uso farmaceutico de los mismos. |
| JP2021528405A (ja) * | 2018-06-18 | 2021-10-21 | ヤンセン ファーマシューティカ エヌ．ベー． | ＲＯＲγｔのモジュレータとしてのアミド置換チアゾール |
| WO2021028645A1 (en) | 2019-08-09 | 2021-02-18 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62226971A (ja) * | 1986-03-13 | 1987-10-05 | ドクトル カ−ル ト−メ− ゲゼルシヤフト ミツト ベシユレンクテル ハフツンク | 新規な置換チアゾ−ルおよびオキサゾ−ル化合物 |
| JP2003515597A (ja) * | 1999-12-02 | 2003-05-07 | グラクソ グループ リミテッド | Ｈｐｐａｒアルファアクチベーターとしての置換オキサゾールおよびチアゾール誘導体 |
| JP2003137865A (ja) * | 1999-11-10 | 2003-05-14 | Takeda Chem Ind Ltd | 含窒素５員複素環化合物 |
| WO2003074495A1 (en) * | 2002-03-01 | 2003-09-12 | Smithkline Beecham Corporation | Hppars activators |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9604242D0 (en) * | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
| IL135177A0 (en) * | 1997-10-02 | 2001-05-20 | Sankyo Co | Amidocarboxylic acid derivatives and pharmaceutical compositions containing the same |
| JP3372923B2 (ja) * | 2000-02-25 | 2003-02-04 | エヌイーシーマイクロシステム株式会社 | 半導体集積回路 |
-
2004
- 2004-11-12 TW TW093134800A patent/TW200526588A/zh unknown
- 2004-11-15 WO PCT/EP2004/012965 patent/WO2005049578A1/en not_active Ceased
- 2004-11-15 DE DE602004015498T patent/DE602004015498D1/de not_active Expired - Fee Related
- 2004-11-15 JP JP2006538823A patent/JP2007511485A/ja active Pending
- 2004-11-15 AT AT04818779T patent/ATE402926T1/de not_active IP Right Cessation
- 2004-11-15 US US10/595,868 patent/US20080021030A1/en not_active Abandoned
- 2004-11-15 ES ES04818779T patent/ES2311179T3/es not_active Expired - Lifetime
- 2004-11-15 EP EP04818779A patent/EP1685113B1/en not_active Expired - Lifetime
- 2004-11-15 AR ARP040104209A patent/AR046625A1/es unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62226971A (ja) * | 1986-03-13 | 1987-10-05 | ドクトル カ−ル ト−メ− ゲゼルシヤフト ミツト ベシユレンクテル ハフツンク | 新規な置換チアゾ−ルおよびオキサゾ−ル化合物 |
| JP2003137865A (ja) * | 1999-11-10 | 2003-05-14 | Takeda Chem Ind Ltd | 含窒素５員複素環化合物 |
| JP2003515597A (ja) * | 1999-12-02 | 2003-05-07 | グラクソ グループ リミテッド | Ｈｐｐａｒアルファアクチベーターとしての置換オキサゾールおよびチアゾール誘導体 |
| WO2003074495A1 (en) * | 2002-03-01 | 2003-09-12 | Smithkline Beecham Corporation | Hppars activators |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013513635A (ja) * | 2009-12-15 | 2013-04-22 | バイエル・クロップサイエンス・アーゲー | １−アルキル−／１−アリール−５−ピラゾールカルボン酸誘導体を調製する方法 |
| JP2013518823A (ja) * | 2010-02-08 | 2013-05-23 | バイオウタ サイエンティフィック マネジメント プロプライエタリー リミテッド | 呼吸器合胞体ウイルス感染症を治療するための化合物 |
| US10653674B2 (en) | 2010-03-30 | 2020-05-19 | Verseon Corporation | Multisubstituted aromatic compounds as inhibitors of thrombin |
| JP2016155812A (ja) * | 2010-03-30 | 2016-09-01 | ヴァーセオン コーポレイション | トロンビンの阻害剤としての多置換芳香族化合物 |
| US9963440B2 (en) | 2010-03-30 | 2018-05-08 | Verseon Corporation | Multisubstituted aromatic compounds as inhibitors of thrombin |
| US9687479B2 (en) | 2013-03-15 | 2017-06-27 | Verseon Corporation | Multisubstituted aromatic compounds as serine protease inhibitors |
| US9951025B2 (en) | 2013-03-15 | 2018-04-24 | Verseon Corporation | Halogenopyrazoles as inhibitors of thrombin |
| US10058541B2 (en) | 2013-03-15 | 2018-08-28 | Verseon Corporation | Multisubstituted aromatic compounds as serine protease inhibitors |
| US10251872B2 (en) | 2013-03-15 | 2019-04-09 | Verseon Corporation | Multisubstituted aromatic compounds as serine protease inhibitors |
| US10189810B2 (en) | 2014-09-17 | 2019-01-29 | Verseon Corporation | Pyrazolyl-substituted pyridone compounds as serine protease inhibitors |
| JP2017535568A (ja) * | 2014-11-27 | 2017-11-30 | カルビスタ・ファーマシューティカルズ・リミテッド | 血漿カリクレイン阻害剤としてのｎ−（（ヘタ）アリールメチル）−ヘテロアリール−カルボキサミド化合物 |
| JP2021185138A (ja) * | 2014-11-27 | 2021-12-09 | カルビスタ・ファーマシューティカルズ・リミテッド | 血漿カリクレイン阻害剤としてのｎ−（（ヘタ）アリールメチル）−ヘテロアリール−カルボキサミド化合物 |
| JP7148683B2 (ja) | 2014-11-27 | 2022-10-05 | カルビスタ・ファーマシューティカルズ・リミテッド | 血漿カリクレイン阻害剤としてのｎ－（（ヘタ）アリールメチル）－ヘテロアリール－カルボキサミド化合物 |
| JP2022180520A (ja) * | 2014-11-27 | 2022-12-06 | カルビスタ・ファーマシューティカルズ・リミテッド | 血漿カリクレイン阻害剤としてのｎ－（（ヘタ）アリールメチル）－ヘテロアリール－カルボキサミド化合物 |
| JP2025000918A (ja) * | 2014-11-27 | 2025-01-07 | カルビスタ・ファーマシューティカルズ・リミテッド | 血漿カリクレイン阻害剤としてのｎ－（（ヘタ）アリールメチル）－ヘテロアリール－カルボキサミド化合物 |
| US10532995B2 (en) | 2015-02-27 | 2020-01-14 | Verseon Corporation | Substituted pyrazole compounds as serine protease inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2311179T3 (es) | 2009-02-01 |
| ATE402926T1 (de) | 2008-08-15 |
| DE602004015498D1 (de) | 2008-09-11 |
| TW200526588A (en) | 2005-08-16 |
| EP1685113B1 (en) | 2008-07-30 |
| WO2005049578A1 (en) | 2005-06-02 |
| US20080021030A1 (en) | 2008-01-24 |
| AR046625A1 (es) | 2005-12-14 |
| EP1685113A1 (en) | 2006-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007511485A (ja) | Ｐｐａｒアゴニストとしての置換ピラゾール | |
| JP3490704B2 (ja) | チアゾールおよびオキサゾール誘導体ならびにそれらの医薬的使用 | |
| KR100706735B1 (ko) | ｈＰＰＡＲ 알파 활성제로서 치환된 옥사졸 및 티아졸유도체 | |
| JP3255930B2 (ja) | ＰＰＡＲ―γに対するアゴニスト活性を有する置換４―ヒドロキシフェニルアルカン酸誘導体 | |
| WO2001060819A1 (en) | Novel isoxazole and thiazole compounds and use thereof as drugs | |
| KR20040007633A (ko) | 심혈관 질환 및 이와 관련된 질환의 치료에 유용한 티아졸또는 옥사졸 유도체 | |
| HUP0400837A2 (hu) | 2-feniltiazol-származékok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények | |
| JP2002531444A (ja) | ベンズアミド誘導体およびａｐｏＢ‐１００分泌阻害剤としてのそれらの使用 | |
| KR20070004769A (ko) | 대사 장애의 치료에 사용되는 화합물, 약제학적 조성물 및그 사용방법 | |
| WO2007129745A1 (ja) | ヘテロアリールアミド低級カルボン酸誘導体 | |
| JPH09505043A (ja) | 置換フェニル化合物 | |
| JP2003535900A (ja) | ベンズアミド誘導体の治療薬としての使用 | |
| JP2004517100A (ja) | ｈＰＰＡＲアルファアゴニストとしての置換オキサゾールおよびチアゾール | |
| WO2002002542A1 (fr) | Compose annulaire a cinq chainons | |
| WO2005026127A1 (ja) | プラスミノゲンアクチベータインヒビター－１阻害剤 | |
| JP2005529965A (ja) | ｈＰＰＡＲ活性化物質としてのフェニルオキシアルカン酸誘導体 | |
| BRPI0616217A2 (pt) | tiazolinonas e oxazolinonas e seus usos como inibidores da ptp1b | |
| TWI245760B (en) | Chemical compounds that activate the alpha subtype of the human peroxisome proliferators activated receptor (hPPAR alpha) and pharmaceutical compositions comprising them for treating hPPAR alpha mediated diseases or conditions | |
| JP2003192591A (ja) | ５員環化合物からなる医薬 | |
| JP2007508270A (ja) | Ｉ．ａ．ジスリピデミアの治療におけるｈｐｐａｒ作用物質として使用するためのチアゾール−２−カルボキシアミド誘導体 | |
| MXPA01001419A (en) | SUBSTITUTED OXAZOLES AND THIAZOLES DERIVATIVES AS hPPAR GAMMA AND hPPAR ALPHA ACTIVATORS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070622 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070622 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101124 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110419 |